Division of Oncology, Hematology and BMT, Department of Pediatrics, BC Children's Hospital/University of British Columbia, Vancouver, BC, Canada.
Expert Rev Hematol. 2011 Jun;4(3):329-42. doi: 10.1586/ehm.11.27.
Chronic graft-versus-host disease (cGVHD ) is a leading cause of allogeneic hematopoietic stem-cell transplantation-related mortality and morbidity. It is an immune-mediated disorder that can target almost any organ in the body, often with devastating consequences. The immune-suppressive medications currently used to treat it are equally toxic and are often not very effective. At this time, our understanding of its pathophysiology is limited. The discovery of potential biomarkers offers new possibilities in the clinical management of cGVHD. They could potentially be used for diagnosing cGVHD, for predicting or evaluating response to therapy and for unique insights into the pathophysiology underlying the clinical manifestations of cGVHD. Understanding the biological origins of these biomarkers can help us construct a more comprehensive and clinically relevant model for the pathogenesis of this disease. In this article, we review existing evidence for candidate biomarkers that have been identified in the framework of how they may contribute to the pathophysiology of cGVHD. Issues regarding the discovery and application of biomarkers are discussed.
慢性移植物抗宿主病（cGVHD）是异基因造血干细胞移植相关死亡和发病的主要原因。它是一种免疫介导的疾病，可以靶向身体几乎任何器官，通常会带来毁灭性的后果。目前用于治疗它的免疫抑制药物同样具有毒性，而且通常效果不是很好。目前，我们对其发病机制的了解是有限的。潜在生物标志物的发现为 cGVHD 的临床管理提供了新的可能性。它们可能被用于诊断 cGVHD，预测或评估对治疗的反应，以及深入了解 cGVHD 临床表现背后的病理生理学。了解这些生物标志物的生物学起源可以帮助我们构建一个更全面和更具临床相关性的疾病发病机制模型。在本文中，我们回顾了在 cGVHD 病理生理学框架内确定的候选生物标志物的现有证据。讨论了生物标志物的发现和应用问题。
